Empower Announces Updates to AI Pilot Program
Empower in partnership with Canntop AI has commenced preliminary testing and analysis to identify key insights for improvements to physician recommended treatment plans
VANCOUVER, March 19, 2019 /CNW/ - EMPOWER CLINICS INC. (CSE: EPW) (Frankfurt: 8EC) ("Empower" or the "Company"), a growth oriented and diversified medical cannabis company, is pleased to provide an update on recent activities by the technical teams at Empower and Canntop AI Inc. ("Canntop"), a subsidiary of Datametrex AI Limited ("Datametrex") to develop a deeper understanding of patient awareness of cannabis-based treatment options and ongoing effectiveness of treatment programs.
The Company has provided select SEO terms and phrases for use in Canntop's artificial intelligence ("AI") platform, targeting two key company markets, Portland, OR and Phoenix, AZ, to gain actionable insights on how consumer social data is generating interest in CBD-based products, alternative pain management options and the use of cannabis-based therapies.
Insights derived from AI are beginning to demonstrate how patients in our key markets are talking about or describing their experience and ideas related to cannabis/CBD-based treatments, and even suggesting recommendations about alternative therapies and their effectiveness in treating a wide array of qualifying conditions,
stated Steven McAuley, Empower's Chief Executive Officer.
We believe the outcomes of our AI efforts, if successful, could position the Company as an educational leader and we plan to collaborate with the industry with the ultimate goal of improving patient care,
said Mr. McAuley.
Canntop's powerful AI tools are helping us analyze the substantial amounts of data in the Empower database and we expect will facilitate the integration of the additional data we expect to derive from the proposed acquisition of the Sun Valley Clinic group, that has a combined 165,000 patients.
We are thrilled that Empower chose Canntop AI to be their partner for their Artificial Intelligence needs. This is a great validation for our business model and we look forward to expanding our program with Empower as they continue to expand their product. We believe that this alliance between Canntop and Empower will create a strong platform for data analysis in the cannabis sector especially in the U.S., providing insurers and health care providers an ideal solution for patient care,
said Michael Frank, Chief Strategy Officer of Datametrex.
- Patient EHR and Management System Empower utilizes a market-leading patient electronic management and POS system that is HIPAA compliant and provides deep insight to patient care.
- Tele-Medicine Platform The Company supports remote patients using its tele-medicine portal, enabling patients who do not live near one of its clinic locations, or are disabled or unable to come to a location, to still benefit from a doctor consultation.
- Website and e-commerce Empower will be commencing the development of its new corporate website and e-commerce store to promote and sell its growing line of CBD-based products under the Sollievo brand and other partner brands.
Empower is a leading owner/operator of a network of physician-staffed clinics focused on helping patients improve and protect their health through innovative uses of medical cannabis. It is expected that Empower's proprietary product line "Sollievo" will offer patients a variety of delivery methods of doctor recommended cannabidiol (CBD) based product options in its clinics, online and at major retailers. With over 120,000 patients, an expanding clinic footprint, a focus on new technologies, including tele-medicine, and an expanded product development strategy, Empower is undertaking new growth initiatives to be positioned as a vertically integrated, diverse, market-leading service provider for complex patient requirements in 2019 and beyond.
Datametrex AI Limited is a technology focused company with exposure to Artificial Intelligence and Machine Learning through its wholly owned subsidiary, Nexalogy (www.nexalogy.com) and Implementing Blockchain technology for secure Data Transfers through its investee company, Graph Blockchain (www.graphblockchain.com).
ON BEHALF OF THE BOARD OF DIRECTORS:
Chief Executive Officer
DISCLAIMER FOR FORWARD-LOOKING STATEMENTS
This news release contains certain "forward-looking statements" or "forward-looking information" (collectively "forward looking statements") within the meaning of applicable Canadian securities laws. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Forward-looking statements can frequently be identified by words such as "plans", "continues", "expects", "projects", "intends", "believes", "anticipates", "estimates", "may", "will", "potential", "proposed" and other similar words, or information that certain events or conditions "may" or "will" occur. Forward-looking statements in this news release include statements regarding: the proposed acquisition of Sun Valley; the expected benefits to be derived from use of the Canntop AI tools; the ability of Canntop's software to assist in integrating Sun Valley data (assuming the successful completion of such transaction); the benefits of CBD based products; and that the Company will be positioned to be a market-leading service provider for complex patient requirements in 2019 and beyond. Such statements are only projections, are based on assumptions known to management at this time, and are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the forward-looking statements, including: that the Canntop software may not be able to properly analyze the Company's information as is expected or at all; that the proposed acquisition of Sun Valley may not be completed on the terms expected or at all; that regulatory proceedings may negatively impact the Company's business; that legislative changes may have an adverse effect on the Company's business and product development; that the Company may not be able to obtain adequate financing to pursue its business plan; general business, economic, competitive, political and social uncertainties; failure to obtain any necessary approvals in connection with the proposed acquisitions and partnerships; and other factors beyond the Company's control. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Readers are cautioned not to place undue reliance on the forward-looking statements in this release, which are qualified in their entirety by these cautionary statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements in this release, whether as a result of new information, future events or otherwise, except as expressly required by applicable laws.